Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA panel to discuss Tamiflu, Relenza adverse events

FDA briefing documents released ahead of Tuesday's Pediatric Advisory Committee meeting recommend new safety warnings for Tamiflu oseltamivir from Roche

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE